Royalty Pharma Plc (RPRX)
64.76
+0.90
(+1.41%)
USD |
NASDAQ |
Oct 26, 16:00
64.88
+0.12
(+0.19%)
After-Hours: 19:17
Royalty Pharma Net Income (Quarterly) : 81.49M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 81.49M |
| March 31, 2026 | 468.26M |
| December 31, 2025 | 356.00M |
| September 30, 2025 | 444.21M |
| June 30, 2025 | 92.64M |
| March 31, 2025 | 434.43M |
| December 31, 2024 | 334.00M |
| September 30, 2024 | 806.36M |
| June 30, 2024 | 194.38M |
| March 31, 2024 | -4.273M |
| December 31, 2023 | 718.00M |
| September 30, 2023 | 122.08M |
| June 30, 2023 | 351.34M |
| March 31, 2023 | 509.09M |
| December 31, 2022 | -610.00M |
| Date | Value |
|---|---|
| September 30, 2022 | 220.41M |
| June 30, 2022 | 491.60M |
| March 31, 2022 | 128.08M |
| December 31, 2021 | 54.00M |
| September 30, 2021 | 221.80M |
| June 30, 2021 | 806.76M |
| March 31, 2021 | 158.98M |
| December 31, 2020 | 367.00M |
| September 30, 2020 | 624.25M |
| June 30, 2020 | 601.98M |
| March 31, 2020 | 109.10M |
| December 31, 2019 | 1.447B |
| September 30, 2019 | 440.03M |
| June 30, 2019 | 178.77M |
| March 31, 2019 | 396.09M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Merck & Co., Inc. | -1.337B |
| Johnson & Johnson | 210.00M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 674.14M |
| Total Expenses (Quarterly) | 656.26M |
| EPS Diluted (Quarterly) | 0.04 |
| Enterprise Value | 39.54B |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 12.09% |
| Earnings Yield | 2.90% |
| Operating Earnings Yield | 4.64% |
| Normalized Earnings Yield | 2.727 |